Targeting Oligometastasis with Stereotactic Ablative Radiation Therapy or Surgery in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review of Prospective Clinical Trials

Vale, 2018, What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis, Ann Oncol, 29, 1249, 10.1093/annonc/mdy071 Parker, 2018, Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial, Lancet, 392, 2353, 10.1016/S0140-6736(18)32486-3 NICE Guideline Updates Team UK, 2019 Mottet, 2019 James, 2016, Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial, Lancet, 387, 1163, 10.1016/S0140-6736(15)01037-5 Gaylis, 2017, Change in prostate cancer presentation coinciding with USPSTF screening recommendations at a community-based urology practice, Urol Oncol, 35, 10.1016/j.urolonc.2017.06.059 Connor, 2020, Cytoreductive treatment strategies for de novo metastatic prostate cancer, Nat Rev Clin Oncol, 17, 168, 10.1038/s41571-019-0284-3 Weichselbaum, 2011, Oligometastases revisited, Nat Rev Clin Oncol, 8, 378, 10.1038/nrclinonc.2011.44 Khoo, 2019, New concepts in prostate cancer management: The conundrum of managing oligometastatic disease in prostate cancer—through the looking glass darkly, Clin Radiol, 74, 865, 10.1016/j.crad.2019.05.003 Sweeney, 2015, Chemohormonal therapy in metastatic hormone-sensitive prostate cancer, N Engl J Med, 373, 737, 10.1056/NEJMoa1503747 Karantanos, 2013, Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches, Oncogene, 32, 5501, 10.1038/onc.2013.206 Roubaud, 2017, Strategies to avoid treatment-induced lineage crisis in advanced prostate cancer, Nat Rev Clin Oncol, 14, 269, 10.1038/nrclinonc.2016.181 Moher, 2015, Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement, Syst Rev, 4, 1, 10.1186/2046-4053-4-1 Connor, 2019 UK SABR Consortium, 2019 Benedict, 2010, Stereotactic body radiation therapy: the report of AAPM task group 101, Med Phys, 37, 4078, 10.1118/1.3438081 Sterne, 2016, ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions, BMJ, 355, i4919, 10.1136/bmj.i4919 Higgins, 2016, A revised tool for assessing risk of bias in randomized trials, Cochrane Database Syst Rev, 10, 29 Canfield, 2011, Rating the quality of evidence and the strength of recommendations using GRADE, World J Urol, 29, 311, 10.1007/s00345-011-0667-2 Siva, 2018, Stereotactic ablative body radiotherapy (SABR) for oligometastatic prostate cancer: a prospective clinical trial, Eur Urol, 74, 455, 10.1016/j.eururo.2018.06.004 Ost, 2017, Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial, J Clin Oncol, 36, 446, 10.1200/JCO.2017.75.4853 O'Shaughnessy, 2017, A pilot study of a multimodal treatment paradigm to accelerate drug evaluations in early-stage metastatic prostate cancer, Urology, 102, 164, 10.1016/j.urology.2016.10.044 Phillips, 2020, Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer. The ORIOLE phase 2 randomized clinical trial, JAMA Oncol, 6, 650, 10.1001/jamaoncol.2020.0147 Ost, 2020, Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence (STOMP): five-year results of a randomized phase II trial, J Clin Oncol, 38, 10, 10.1200/JCO.2020.38.6_suppl.10 Moreno AJC. Phase II study of SBRT as treatment for oligometastases in prostate Cancer. NCT02192788. https://clinicaltrials.gov/ct2/show/NCT02192788. Khoo V. Conventional care versus radioablation (stereotactic body radiotherapy) for extracranial oligometastases (CORE). NCT02759783. https://clinicaltrials.gov/ct2/show/NCT02759783. Cheung P, Tamim Niazi M. Local ablative therapy for hormone sensitive oligometastatic prostate cancer (PLATON). https://clinicaltrials.gov/ct2/show/NCT03784755. Connor MJ, Ahmed HU. Additional treatments to the local tumour for metastatic prostate cancer: assessment of novel treatment algorithms (IP2-ATLANTA). NCT03763253. https://clinicaltrials.gov/ct2/show/NCT03763253. Pienta K. A study of definitive therapy to treat prostate cancer (oligo-mets). NCT02716974. https://clinicaltrials.gov/ct2/show/NCT02716974. Parikh, 2019, Systemic and tumor-directed therapy for oligometastatic prostate cancer: study protocol for a phase II trial for veterans with de novo oligometastatic disease, BMC Cancer, 19, 291, 10.1186/s12885-019-5496-5 Dandapani S. Radium Ra 223 dichloride, hormone therapy and stereotactic body radiation therapy in treating patients with metastatic prostate cancer. NCT03361735. https://clinicaltrials.gov/ct2/show/NCT03361735. Blanchard P. Prostate-cancer treatment using stereotactic radiotherapy for oligometastases ablation in hormone-sensitive patients (PRESTO). NCT04115007. https://clinicaltrials.gov/ct2/show/NCT04115007. Golden, 2015, Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial, Lancet Oncol, 16, 795, 10.1016/S1470-2045(15)00054-6 Oronsky, 2018, Case series: abscopal benefit of surgery in 3 immunotherapy-treated patients with unresectable cancer, J Invest Med High Impact Case Rep, 6 Guisier, 2019, A rationale for surgical debulking to improve anti-PD1 therapy outcome in non small cell lung cancer, Sci Rep, 9, 16902, 10.1038/s41598-019-52913-z Golden, 2013, An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer, Cancer Immunol Res, 1, 365, 10.1158/2326-6066.CIR-13-0115 Levy, 2016, Can immunostimulatory agents enhance the abscopal effect of radiotherapy?, Eur J Cancer, 62, 36, 10.1016/j.ejca.2016.03.067 Mole, 1953, Whole body irradiation—radiobiology or medicine?, Br J Radiol, 26, 234, 10.1259/0007-1285-26-305-234 Gundem, 2015, The evolutionary history of lethal metastatic prostate cancer, Nature, 520, 353, 10.1038/nature14347 Robinson, 2015, Integrative clinical genomics of advanced prostate cancer, Cell, 161, 1215, 10.1016/j.cell.2015.05.001 De Bruycker, 2020, PEACE V—Salvage treatment of OligoRecurrent nodal prostate cancer metastases (STORM): a study protocol for a randomized controlled phase II trial, BMC Cancer, 20, 406, 10.1186/s12885-020-06911-4 Chi, 2019, Apalutamide for metastatic, castration-sensitive prostate cancer, N Engl J Med, 381, 13, 10.1056/NEJMoa1903307 Davis, 2019, Enzalutamide with standard first-line therapy in metastatic prostate cancer, N Engl J Med, 381, 121, 10.1056/NEJMoa1903835 James, 2017, Abiraterone for prostate cancer not previously treated with hormone therapy, N Engl J Med, 377, 338, 10.1056/NEJMoa1702900 Ost, 2015, Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature, Eur Urol, 67, 852, 10.1016/j.eururo.2014.09.004 Palma, 2019, Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial, Lancet, 393, 2051, 10.1016/S0140-6736(18)32487-5 Sogono, 2019, SABR-COMET: a new paradigm of care lights up the twilight of metastatic disease, Ann Transl Med, 7, 615, 10.21037/atm.2019.10.96 Palma D, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial. J Clin Oncol. In press. https://doi.org/10.1200/JCO.20.00818. Han, 2018, Impact of 68Ga-PSMA PET on the management of patients with prostate cancer: a systematic review and meta-analysis, Eur Urol, 74, 179, 10.1016/j.eururo.2018.03.030 Connor, 2020, Survival in oligometastatic prostate cancer—a new dawn or the Will Rogers phenomenon?, JAMA Oncol, 6, 185, 10.1001/jamaoncol.2019.4724 Supiot, 2015, OLIGOPELVIS – GETUG P07: A multicentre phase II trial of combined salvage radiotherapy and hormone therapy in oligometastatic pelvic node relapses of prostate cancer, BMC Cancer, 15, 646, 10.1186/s12885-015-1579-0 Fraser, 2019, What is oligometastatic prostate cancer?, Eur Urol Focus, 5, 159, 10.1016/j.euf.2018.12.009 Friedlander, 2017, Personalizing therapy for metastatic prostate cancer: the role of solid and liquid tumor biopsies, Am Soc Clin Oncol Educ Book, 37, 358, 10.14694/EDBK_175510 Lussier, 2012, Oligo- and polymetastatic progression in lung metastasis (es) patients is associated with specific microRNAs, PLoS One, 7, e50141, 10.1371/journal.pone.0050141 Pitroda, 2018, Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis, Nat Commun, 9, 1793, 10.1038/s41467-018-04278-6